GSK Reports Strong Third Quarter 2026 Financial Results

GSK reported third-quarter 2026 sales of £8.9 billion, up 5% at constant exchange rates, and core EPS of 54.6 pence, above the 50.4-pence analyst consensus. Specialty Medicines led growth, with sales up 15%, including increases of 10% in HIV products and 23% in oncology. GSK reaffirmed its 2026 guidance, expecting turnover growth in the upper half of its 3%–5% range and core EPS growth in the lower half of its 7%–9% range, both at constant exchange rates. The company also cited regulatory approvals and new Phase III trials in its R&D pipeline, alongside a £328 million charge for its ongoing savings program.